Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Much Is the Global Therapeutic BCG Vaccines Market Valued at Present and by 2029?

The market size for therapeutic bcg vaccines has seen consistent growth over the recent years. The market, which stands at $56.47 billion in 2024, is projected to grow to $59.09 billion in 2025, indicating a compound annual growth rate (CAGR) of 4.6%. The observed growth during the historical period is linked to factors like government efforts towards tuberculosis control, modulation of the immune system, worldwide immunization drives, treatment of bladder cancer, increased investment in vaccine production, and the rise of drug-resistant tuberculosis strains.

Expectations are high for substantial growth in the therapeutic bcg vaccines market in the upcoming years, potentially reaching “$75.46 billion in 2029”, with an anticipated compound annual growth rate (CAGR) of 6.3%. This projected growth for the period is largely due to factors such as the exploration of other indications, accelerated research in immunotherapy, the worldwide fight against rising infectious diseases, regulatory support for vaccine research and development, and a concentrated effort towards eradicating tuberculosis. The period also sees groundbreaking developments in vaccine technology, enhancing supply chain processes, unifying the market and forming partnerships, educating and creating awareness among patients, exploring alternative methods for vaccine delivery, and implementing personalized medicine strategies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9178&type=smp

#What Drivers Are Influencing Growth In The Therapeutic BCG Vaccines Market?

The escalating count of global tuberculosis (TB) instances is driving the expansion of the therapeutic BCG vaccine market. TB is a potentially lethal infectious disease primarily affecting the lungs. The infection can be transmitted from one person to another via airborne droplets containing bacteria that are released during coughing or sneezing. BCG vaccines are utilized to trigger the immune system to combat these infections, yet they do not induce TB since the bacteria are feeble. The vaccine consistently safeguards against the most severe types of TB, such as adolescent TB meningitis. The capacity of the BCG vaccine to deliver protection against tuberculosis and boost immunity has led to a rise in the utilization of therapeutic BCG vaccines. As an example, in February 2024, the UK Health Security Agency, a government agency in the UK, released a report revealing a 10.7% surge in TB cases in England in 2023 with 4,850 cases reported, a significant increase from 4,380 in 2022. Consequently, the growing prevalence of TB globally is accelerating the expansion of the therapeutic BCG vaccine market.

What Are The Main Segments Identified In The Therapeutic BCG Vaccines Market Research?

The therapeutic bcg vaccines market covered in this report is segmented –

1) By Type: Therapy BCG, Immune BCG

2) By Demographics: Pediatrics, Adults

3) By End Use: Hospitals, Clinics, Other End Users

Subsegments:

1) By Therapy BCG: Intravesical BCG, Injectable BCG

2) By Immune BCG: BCG For Immune Enhancement, BCG For Allergy Treatment

Which Emerging Trends And Strategic Shifts Are Shaping The Therapeutic BCG Vaccines Market?

A prominent trend in the therapeutic BCG vaccine market involves strategic alliances between major companies operating within this industry. These corporations are looking to maintain market dominance by collaborating with other influential players. For example, in May 2024, ImmunityBio, a biotechnological firm based in the United States, formed a partnership with Serum Institute of India, a biotechnology and biopharmaceuticals company from India. This collaboration aims to ensure the availability of the Bacillus Calmette-Guerin (BCG) vaccine for all forms of cancer. The partnership revolves around producing the standard BCG (sBCG), which is certified for usage outside America, and a new recombinant BCG (iBCG) that is presently being tested. The intended use of iBCG is in conjunction with ImmunityBio’s ANKTIVA (nogapendekin alfa inbakicept-PMLN) for authorized and potential future indications, depending on regulatory approvals.

Which Companies Play A Key Role In The Development Of The Therapeutic BCG Vaccines Market?

Major companies operating in the therapeutic bcg vaccines market include Merck & Co Inc., Sanofi Pasteur, Japan BCG Laboratory, China National Biotec Group, Serum Institute of India Pvt. Ltd., InterVax Ltd., GreenSignal Bio Pharma Limited, Statens Serum Institute, AJ Vaccines, Bul Bio-National Center of Infectious and Parasitic Diseases Ltd, Biomed Lublin S.A., Microgen, Taj Pharma Ltd., PT Bio Farma, Torlak Institute of Virology, Bacille Bilie Calmette-Guerin Laboratory, China Biotechnology Co Ltd., Bharat Biotech International Ltd., Biological E. Limited, Shanghai Institute of Biological Products Co. Ltd., Cipla Limited, Instituto Butantan

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/therapeutic-bcg-vaccines-global-market-report

What Are The Key Regional Developments Shaping The Therapeutic BCG Vaccines Market?

Asia-Pacific was the largest region in the therapeutic BCG vaccines market in 2024. The regions covered in the therapeutic bcg vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=9178&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model